Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP^® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults.

ABSTRACT: Background: Several techniques are under investigation to improve the immunogenicity of HIV-1 DNA vaccine candidates. DNA vaccines are advantageous due to their ease of design, expression of multiple antigens, and safety.

Methods

The HVTN 098 trial assessed the PENNVAX^®-GP DNA vaccine (encoding HIV env, gag, pol) administered with or without plasmid IL-12 at 0-, 1-, 3-, and 6-month timepoints via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, adult participants. We report on safety, tolerability, and acceptability.

Results

HVTN 098 enrolled 94 participants: 85 received PENNVAX^®-GP and nine received placebo. Visual analog scale (VAS) pain scores immediately after each vaccination were lower in the ID/EP

SUBMITTER: Edupuganti S 

PROVIDER: S-EPMC7762306 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature